The rules for designing cyclic peptides with drug-like properties are unclear. Two studies now show how cyclic peptide libraries can be created to optimize properties such as cell permeability before screening for binding activity. The approach has led to a macrocyclic peptide inhibitor for KRAS that has reached clinical trials.
This is a preview of subscription content, log in via an institution to check access.
References
Buyanova, M. & Pei, D. Trends Pharmacol. Sci. 43, 234–248 (2022).
Ji, X., Nielsen, A. L. & Heinis, C. Angew. Chem. Int. Ed. 63, e202308251 (2023).
Vinogradov, A. A., Yin, Y. & Suga, H. J. Am. Chem. Soc. 141, 4167–4181 (2019).
Tanada, M. et al. J. Am. Chem. Soc. 145, 16610–16620 (2023).
Ohta, A. et al. J. Am. Chem. Soc. 145, 24035–24051 (2023).
Hillig, R. C. et al. Proc. Natl Acad. Sci. 116, 2551–2560 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pal, S., ‘t Hart, P. Imbuing peptide libraries with drug-likeness. Nat Chem Biol 20, 140–141 (2024). https://doi.org/10.1038/s41589-023-01524-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-023-01524-x
- Springer Nature America, Inc.